Cargando…
Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome
BACKGROUND/AIM: Cholinergic syndrome frequently occurs within the first 24 h after irinotecan injection. We evaluated the prophylactic effect of scopolamine butylbromide on irinotecan-related cholinergic syndrome. PATIENTS AND METHODS: Fifty-nine patients who received irinotecan-based regimens at ou...
Autores principales: | Iihara, Hirotoshi, Fujii, Hironori, Yoshimi, Chiaki, Kobayashi, Ryo, Matsuhashi, Nobuhisa, Takahashi, Takao, Yoshida, Kazuhiro, Suzuki, Akio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394464/ https://www.ncbi.nlm.nih.gov/pubmed/30564875 http://dx.doi.org/10.1007/s00280-018-3736-z |
Ejemplares similares
-
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy
por: Iihara, Hirotoshi, et al.
Publicado: (2015) -
Neonatal treatment with scopolamine butylbromide prevents metabolic dysfunction in male rats
por: Malta, Ananda, et al.
Publicado: (2016) -
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018) -
Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series
por: Takeuchi, Ippei, et al.
Publicado: (2015) -
Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)